CD8A and neoplasm: Another CXCR4 antagonist, BL-8040 (Motixafortide), in combination with programmed death 1 (PD-1, also known as CD279) antagonist pembrolizumab increases CD8+ T cell tumor infiltration and decreases tumor cell density (COMBAT trial, NCT02826486) [54].